Sustained deep molecular response over eight years after discontinuation of imatinib for chronic myeloid leukemia

DOI Web Site PubMed

Bibliographic Information

Other Title
  • Imatinib中止後に8年間にわたってdeep molecular responseが継続している慢性骨髄性白血病
  • 症例報告 Imatinib中止後に8年間にわたってdeep molecular responseが継続している慢性骨髄性白血病
  • ショウレイ ホウコク Imatinib チュウシ ゴ ニ 8ネンカン ニ ワタッテ deep molecular response ガ ケイゾク シテ イル マンセイ コツズイセイ ハッケツビョウ

Search this article

Description

A 72-year-old female was diagnosed with chronic phase chronic myeloid leukemia (CML) in 2001. After a short course of treatment with hydroxycarbamide, imatinib (IM) 400 mg was started. A major molecular response was presumably acquired 10 months later. IM was discontinued after treatment for 47 months in November 2005. At the same time, BCR-ABL transcript was undetectable by nested RT-PCR assay, which was equivalent to <0.00138% BCR-ABL according to the international scale. The patient is still under observation with no additional therapy, and BCR-ABL has remained negative for 102 months, to date. Furthermore, interferon was never used in this patient. IM has dramatically improved the prognosis of CML. Since no cure has yet been established, patients are recommended to continue treatment even after achieving deep molecular responses. There are several ongoing clinical trials challenging the discontinuation of IM, but long-term observation is still lacking. The sustained deep molecular response, exceeding eight years, experienced in this patient is potentially encouraging.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 55 (12), 2414-2417, 2014

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top